The FDA has given compounding pharmacies and facilities a deadline of April 22, 2025, or May 22, 2025 (depending on the type of compounding pharmacy or facility) to stop offering compounded semaglutide
Raffo writes that, These combined effects are particularly intriguing for orthopedics because many musculoskeletal injuries (Achilles tendon ruptures, rotator cuff tears, chronic tendinopathies) occur in precisely those areas where blood flow is limited and healing is frustratingly slow. However, to be clear, BPC-157 is not FDA approved
The selective action of AOD-9604 contributes to a more favorable safety profile compared to growth hormone for most individuals seeking fat loss
Based on announcements in early 2026, the FDA and HHS signaled reclassifying a group of peptides, including BPC-157, TB-500, and injectable GHK-Cu, toward Category 1, which makes them eligible for use by licensed compounding pharmacies preparing individualized medications under a prescription